- Home
- KBDC vs SPRY Comparison
KBDC vs SPRY Comparison
Compare KBDC & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KBDC | SPRY |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 918.9M | 823.2M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KBDC | SPRY |
|---|---|---|
| Price | $14.73 | $7.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $15.50 | ★ $40.00 |
| AVG Volume (30 Days) | 267.8K | ★ 1.7M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | ★ 13.16% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | $193.84 | $87.40 |
| Revenue Next Year | $9.00 | $81.64 |
| P/E Ratio | $34.49 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.06 | $6.66 |
| 52 Week High | $16.40 | $18.63 |
Technical Indicators
Market Signals| Indicator | KBDC | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 51.78 | 35.06 |
| Support Level | $14.02 | $6.66 |
| Resistance Level | $15.02 | $8.61 |
| Average True Range (ATR) | 0.39 | 0.52 |
| MACD | -0.04 | -0.10 |
| Stochastic Oscillator | 31.67 | 14.57 |
Price Performance
Historical ComparisonAbout KBDC Kayne Anderson BDC Inc.
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company, investing mainly in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation mainly through debt investments in middle-market companies.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.